Mind Club

Data as of 11.07.2026 · Primary sources linked · NOT INVESTMENT ADVICE

Disease Pipeline Tools Obesity

Obesity

Programs, trials, and reported weight change for obesity and overweight.

Data as of 11.07.2026

All studies

Setmelanotide

DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor (MC4R) Pathway

Rhythm · Phase 2 · Completed · Enrollment 164

NCT04963231

Y axis: Change in body weight from baseline, %

0-504812162024Stage 1: Setmelanotide (Open-Label), week 16, -3.94%Stage 1: Setmelanotide (Open-Label)

X axis: Weeks since randomization

Cited trial source. Only weeks the source states.

  • Stage 1: Setmelanotide (Open-Label): week 16 -3.94%

One reported week is a point at that week. It is not a line from 0%. A solid line connects two or more reported weeks.